

Supplementary Data

SUPPLEMENTARY TABLE S1. ASSESSMENT OF HEPATOTOXICITY

Cohort	GCV	2nd		3rd		5th		8th	
ssAAV8-HLP-TK	-	24.0 ±	2.83	30 ±	2.83	23.5 ±	3.54	39.0 ±	14.00
	+	26.0 ±	4.24	38 ±	7.07	176.0 ±	31.11	2899.6 ±	1196.53
ssAAV8-HLP-TK-122aT4	-	20.5 ±	3.54	24 ±	5.66	19.3 ±	3.06	19.0 ±	2.16
	+	28.5 ±	0.71	23 ±	8.49	20.5 ±	3.54	55.0 ±	25.06

Animals from each cohort were bled at 2, 3, 5, and 8 days after GCV treatment. Blood samples were collected by tail vein bleeding into a coagulant containing tube, and aspartate aminotransferase (AST) activities were measured using a Beckman Coulter AU680 clinical chemistry analyzer.